Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment

Name: Phase III Study to Evaluate the Safety, Efficacy, and Impact on Quality of Life of Capivasertib Alongside Standard-of-care Endocrine Treatment in Patients With HR+/HER2- Advanced Breast Cancer and Progression on Prior Endocrine-based Treatment
Published: 2025
License: Public Domain

Women's Cancer Study Group GmbH · 2025

ClinicalTrials.gov · Datasets · License: Public Domain · 2025

Open Source ↗

advanced breast-cancer ehealth progression

breast cancer, hr-positive breast cancer, advanced breast cancer, metastatic breast cancer, her2-negative breast cancer, advanced, metastatic, metastatic, progression, hr+, her2-, capivasertib, ehealth

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Record · ID 869704
Retrieved via Conceptio — every document is proof-bundled with source, license, and retrieval metadata.